Testosterone/dutasteride
From Wikipedia, the free encyclopedia
The printable version is no longer supported and may have rendering errors. Please update your browser bookmarks and please use the default browser print function instead.
Combination drug
Pharmaceutical compound
| Combination of | |
|---|---|
| Testosterone | Androgen |
| Dutasteride | 5α-Reductase inhibitor |
| Clinical data | |
| Other names | Dutasteride/testosterone |
Testosterone/dutasteride is a combination formulation of testosterone, an androgen, and dutasteride, a 5α-reductase inhibitor, which was under development by GlaxoSmithKline for the treatment of hypogonadism (low testosterone levels) in men in the 2000s.[1] It reached phase II clinical trials prior to the discontinuation of its development.[1]
References
- ^ a b "Testosterone/dutasteride". AdisInsight. Springer Nature Switzerland AG.
 | This drug article relating to the genito-urinary system is a stub. You can help Wikipedia by expanding it. |
Hidden categories:
- Articles with short description
- Short description matches Wikidata
- Short description is different from Wikidata
- Chemical articles without CAS registry number
- Articles without EBI source
- Chemical pages without ChemSpiderID
- Chemical pages without DrugBank identifier
- Articles without KEGG source
- Articles without InChI source
- Articles without UNII source
- Drugs missing an ATC code
- Drugs with no legal status
- Articles containing unverified chemical infoboxes
- Drugs that are a combination of chemicals
- All stub articles